

Qwo™ (collagenase clostridium histolyticum-aaes) – New drug approval

- On July 6, 2020, Endo announced the FDA approval of Qwo (collagenase clostridium histolyticum-aaes), for the treatment of moderate to severe cellulite in the buttocks of adult women.
- Qwo is the first FDA-approved injectable treatment for cellulite.
- The efficacy of Qwo was established in two identical, randomized, double-blind, placebo-controlled studies in adult women with cellulite (study 1: N = 423; study 2: N = 420). The primary endpoint was the proportion of 2-level multi-component responders at day 71 post-randomization. A 2-level multi-component responder was defined as having an improvement of at least 2 levels of cellulite severity from baseline on both the Clinician Reported Photonumeric Cellulite Severity Scale (CR-PCSS) and the Patient Reported Photonumeric Cellulite Severity Scale (PR-PCSS) in the target buttock.
 - In study 1, the primary endpoint was met in 8% of Qwo patients vs. 2% with placebo (adjusted treatment difference: 6; 95% CI: 2, 10).
 - In study 2, primary endpoint was met in 6% of Qwo patients vs. < 1% with placebo (adjusted treatment difference: 5; 95% CI: 2, 8).
- Qwo is contraindicated in:
 - Patients with a history of hypersensitivity to collagenase or to any of the excipients
 - The presence of infection at the injection sites.
- Warnings and precautions for Qwo include hypersensitivity reactions, injection site bruising, and substitution of collagenase products.
- The most common adverse reactions (≥ 1%) with Qwo use were related to the injection site (bruising, pain, nodule, pruritus, erythema, discoloration, swelling, and warmth).
- Qwo is injected subcutaneously at a dose of 0.84 mg per treatment area. Treatment should be repeated every 21 days for 3 treatment visits.
 - A treatment area is defined as a single buttock receiving up to 12 injections, 0.3 mL each (up to a total of 3.6 mL), of Qwo.
 - A treatment visit may consist of up to 2 treatment areas.
 - Refer to the Qwo drug label for additional administration recommendations.
- Endo is expected to make Qwo available at aesthetic healthcare practitioner's offices starting in spring 2021. Qwo will be available as a 0.92 mg or 1.84 mg lyophilized powder in single-dose vials.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.